- Home
- CHNR vs CERO Comparison
CHNR vs CERO Comparison
Compare CHNR & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- CERO
- Stock Information
- Founded
- CHNR N/A
- CERO 2017
- Country
- CHNR China
- CERO United States
- Employees
- CHNR N/A
- CERO N/A
- Industry
- CHNR Precious Metals
- CERO
- Sector
- CHNR Basic Materials
- CERO
- Exchange
- CHNR Nasdaq
- CERO Nasdaq
- Market Cap
- CHNR 5.3M
- CERO 6.1M
- IPO Year
- CHNR 1995
- CERO N/A
- Fundamental
- Price
- CHNR $4.96
- CERO $5.39
- Analyst Decision
- CHNR
- CERO Strong Buy
- Analyst Count
- CHNR 0
- CERO 2
- Target Price
- CHNR N/A
- CERO $45.00
- AVG Volume (30 Days)
- CHNR 289.1K
- CERO 82.8K
- Earning Date
- CHNR 11-11-2025
- CERO 11-18-2025
- Dividend Yield
- CHNR N/A
- CERO N/A
- EPS Growth
- CHNR N/A
- CERO N/A
- EPS
- CHNR N/A
- CERO N/A
- Revenue
- CHNR N/A
- CERO N/A
- Revenue This Year
- CHNR N/A
- CERO N/A
- Revenue Next Year
- CHNR N/A
- CERO N/A
- P/E Ratio
- CHNR N/A
- CERO N/A
- Revenue Growth
- CHNR N/A
- CERO N/A
- 52 Week Low
- CHNR $3.16
- CERO $4.27
- 52 Week High
- CHNR $9.04
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- CHNR 61.22
- CERO 40.84
- Support Level
- CHNR $4.81
- CERO $5.18
- Resistance Level
- CHNR $5.26
- CERO $5.45
- Average True Range (ATR)
- CHNR 0.52
- CERO 0.24
- MACD
- CHNR -0.02
- CERO 0.09
- Stochastic Oscillator
- CHNR 29.98
- CERO 56.96
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.